SG Americas Securities LLC Increases Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SG Americas Securities LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 96.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 151,482 shares of the biopharmaceutical company’s stock after buying an additional 74,433 shares during the quarter. SG Americas Securities LLC’s holdings in Esperion Therapeutics were worth $333,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Wasatch Advisors LP increased its holdings in Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after acquiring an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares in the last quarter. State Street Corp increased its holdings in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after purchasing an additional 99,802 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Esperion Therapeutics by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after buying an additional 19,588 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Esperion Therapeutics by 71.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 295,378 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ESPR shares. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $7.00 target price on shares of Esperion Therapeutics in a report on Thursday, January 23rd. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, January 23rd. Finally, Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and a consensus target price of $7.25.

Esperion Therapeutics Stock Up 3.9 %

Shares of ESPR opened at $1.88 on Wednesday. Esperion Therapeutics, Inc. has a 52-week low of $1.58 and a 52-week high of $3.94. The company has a market cap of $370.44 million, a PE ratio of -2.94 and a beta of 1.01. The business has a fifty day moving average of $2.38 and a 200 day moving average of $2.14.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same period in the previous year, the business earned ($0.37) EPS. As a group, research analysts anticipate that Esperion Therapeutics, Inc. will post -0.28 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.